Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive

The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 55; no. 1; pp. 58 - 67
Main Authors Boursier, Jérôme, de Ledinghen, Victor, Zarski, Jean-Pierre, Fouchard-Hubert, Isabelle, Gallois, Yves, Oberti, Frédéric, Calès, Paul
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2012
Wiley
Wolters Kluwer Health, Inc
Wiley-Blackwell
Subjects
Online AccessGet full text
ISSN0270-9139
1527-3350
1527-3350
DOI10.1002/hep.24654

Cover

Abstract The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 (“successive algorithms”). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10−3) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10−3). Similarly, successive BA had significantly (P ≤ 10−3) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10−3). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012;55:58–67)
AbstractList The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F greater than or equal to 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F greater than or equal to 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10 super(-3)) lower diagnostic accuracy (87.3%) than individual SAFE for F greater than or equal to 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10 super(-3)). Similarly, successive BA had significantly (P less than or equal to 10 super(-3)) lower diagnostic accuracy (84.7%) than individual BA for F greater than or equal to 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10 super(-3)). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012; 55:58-67)
The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy.UNLABELLEDThe sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy.SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis.CONCLUSIONSAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis.
The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10-3) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10-3). Similarly, successive BA had significantly (P ≤ 10-3) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10-3). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012;55:58-67)
UNLABELLED: The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. CONCLUSION: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis.
The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis.
The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 (“successive algorithms”). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10−3) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10−3). Similarly, successive BA had significantly (P ≤ 10−3) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10−3). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012;55:58–67)
Author de Ledinghen, Victor
Oberti, Frédéric
Zarski, Jean-Pierre
Fouchard-Hubert, Isabelle
Boursier, Jérôme
Gallois, Yves
Calès, Paul
Author_xml – sequence: 1
  givenname: Jérôme
  surname: Boursier
  fullname: Boursier, Jérôme
  email: JeBoursier@chu-angers.fr
  organization: Department of Hepatogastroenterology, University Hospital, Angers, France
– sequence: 2
  givenname: Victor
  surname: de Ledinghen
  fullname: de Ledinghen, Victor
  organization: Department of Hepatogastroenterology, Haut-Lévêque University Hospital, Pessac, France
– sequence: 3
  givenname: Jean-Pierre
  surname: Zarski
  fullname: Zarski, Jean-Pierre
  organization: Department of Liver-Gastroenterology, University Hospital, Grenoble, France
– sequence: 4
  givenname: Isabelle
  surname: Fouchard-Hubert
  fullname: Fouchard-Hubert, Isabelle
  organization: Department of Hepatogastroenterology, University Hospital, Angers, France
– sequence: 5
  givenname: Yves
  surname: Gallois
  fullname: Gallois, Yves
  organization: HIFIH Laboratory, UPRES 3859, Institut Fédératif de Recherche (IFR) 132, University of Angers, Pôle de Recherche et d'Enseignement Supérieur Université Nantes Angers Le Mans (PRES UNAM), France
– sequence: 6
  givenname: Frédéric
  surname: Oberti
  fullname: Oberti, Frédéric
  organization: Department of Hepatogastroenterology, University Hospital, Angers, France
– sequence: 7
  givenname: Paul
  surname: Calès
  fullname: Calès, Paul
  organization: Department of Hepatogastroenterology, University Hospital, Angers, France
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25543199$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21898504$$D View this record in MEDLINE/PubMed
https://hal.science/hal-00866967$$DView record in HAL
BookMark eNp90ltv0zAUB_AIDbELPPAFkCWEgIdsvsYxb1M1VlDFReLyaJ06TuuR2MVOO_oB-N64tOvQJPYSK9Hvf5zj4-PiwAdvi-IpwacEY3o2t4tTyivBHxRHRFBZMibwQXGEqcSlIkwdFscpXWGMFaf1o-KQklrVAvOj4vco9AuILgWPQousm80H1DiY-ZAGZxB0sxDdMO8TakNEnVvZiFo3jSG5hJxHeW8Y3JBfRm-Qt9f_JiBa1If8WERrXLIIfIOsH1y03RrlJpxfQcolHxcPW-iSfbJbT4qvby--jMbl5OPlu9H5pDS8lrxU1MgazJQJQlpGiVTcWGWAV4bLBmoDtgZBFCEUS8MkZ7USkliwTSMaQthJ8Xpbdw6dXkTXQ1zrAE6Pzyd68w3juqpUJVcb-3JrFzH8XNo06N4lY7sOvA3LpBWhFVNciixf3SuJlFVV1YKqTJ_foVdhGX3uOatsqGCCZvVsp5bT3jb7P70ZWwYvdgCSga6N4PP53johOCNK3fZr8rxStO2eEKw3V0fn8em_VyfbszvWuCGPNvghguvuS1y7zq7_X1qPLz7dJMptwqXB_tonIP7QlWRS6O8fLjVjY_4N88_6PfsDc6HikA
CODEN HPTLD9
CitedBy_id crossref_primary_10_1016_j_jhep_2019_04_020
crossref_primary_10_1016_j_cmi_2016_09_017
crossref_primary_10_1016_j_dld_2018_11_016
crossref_primary_10_1111_liv_12327
crossref_primary_10_1111_liv_13536
crossref_primary_10_1016_S0973_6883_12_60077_2
crossref_primary_10_17816_0869_2106_2021_27_4_373_384
crossref_primary_10_1016_j_cegh_2020_04_011
crossref_primary_10_3389_fphar_2021_734090
crossref_primary_10_1016_j_critrevonc_2013_07_005
crossref_primary_10_1002_hep_25993
crossref_primary_10_4254_wjh_v9_i6_310
crossref_primary_10_1016_j_jhep_2024_04_007
crossref_primary_10_1016_j_ijmedinf_2024_105373
crossref_primary_10_19163_2307_9266_2019_7_6_356_362
crossref_primary_10_1517_17530059_2012_691878
crossref_primary_10_1016_S1665_2681_19_31456_5
crossref_primary_10_1002_hep4_1161
crossref_primary_10_1016_j_jhep_2017_02_011
crossref_primary_10_1016_j_jhep_2016_04_023
crossref_primary_10_1186_s12876_022_02108_0
crossref_primary_10_1038_srep01065
crossref_primary_10_1097_MEG_0000000000000346
crossref_primary_10_1007_s10620_023_08085_y
crossref_primary_10_1136_bmjgast_2019_000316
crossref_primary_10_1136_gutjnl_2018_317593
crossref_primary_10_1111_apt_13954
crossref_primary_10_1155_2024_5540648
crossref_primary_10_3748_wjg_v22_i4_1367
crossref_primary_10_3310_hta19090
crossref_primary_10_3389_fphar_2016_00159
crossref_primary_10_1111_jvh_13548
crossref_primary_10_1016_j_jhep_2016_10_006
crossref_primary_10_1016_j_jhep_2017_01_003
crossref_primary_10_1002_hep_25517
crossref_primary_10_3390_transplantology4020008
crossref_primary_10_1007_s10620_015_3682_0
crossref_primary_10_2463_mrms_2014_0150
crossref_primary_10_1016_j_jhep_2014_02_029
crossref_primary_10_5604_01_3001_0009_8589
crossref_primary_10_1007_s11377_015_0034_8
crossref_primary_10_1371_journal_pone_0173506
crossref_primary_10_2217_cpr_12_18
crossref_primary_10_4254_wjh_v10_i1_105
crossref_primary_10_3748_wjg_v22_i29_6663
crossref_primary_10_4103_2153_3539_157782
crossref_primary_10_1128_CMR_00037_16
crossref_primary_10_4103_ejim_ejim_46_19
crossref_primary_10_1016_S0140_6736_15_00349_9
crossref_primary_10_1097_SGA_0000000000000430
crossref_primary_10_1016_S2468_1253_17_30116_4
crossref_primary_10_1002_hep_26144
crossref_primary_10_1111_apt_15529
crossref_primary_10_1002_hep_27950
crossref_primary_10_1097_RUQ_0000000000000209
crossref_primary_10_1016_j_cgh_2015_07_030
crossref_primary_10_1097_MCG_0b013e318266fe70
crossref_primary_10_1097_MEG_0000000000000182
crossref_primary_10_1097_MCG_0000000000000788
crossref_primary_10_1111_j_1365_2516_2012_02854_x
crossref_primary_10_1016_j_jhep_2015_04_006
crossref_primary_10_14218_JCTH_2017_00038
crossref_primary_10_1053_j_gastro_2012_02_017
crossref_primary_10_1093_bmb_ldu031
crossref_primary_10_1016_j_jhepr_2020_100067
crossref_primary_10_1007_s40265_019_01126_9
crossref_primary_10_1148_radiol_2015150619
crossref_primary_10_1148_radiol_231220
crossref_primary_10_5812_hepatmon_6229
crossref_primary_10_1097_HEP_0000000000000843
crossref_primary_10_1097_01_NPR_0000515423_38284_28
crossref_primary_10_1146_annurev_physiol_021115_105331
crossref_primary_10_1016_j_clinre_2012_08_002
crossref_primary_10_7326_M15_0785
crossref_primary_10_1136_gutjnl_2020_322976
crossref_primary_10_1111_hepr_12696
crossref_primary_10_1093_cid_cit245
crossref_primary_10_1155_2015_809289
crossref_primary_10_5812_hepatmon_5106
crossref_primary_10_1007_s11606_017_4280_y
crossref_primary_10_1186_s12967_016_0952_3
crossref_primary_10_3748_wjg_v20_i32_11033
crossref_primary_10_1159_000374097
crossref_primary_10_3892_mmr_2015_3299
crossref_primary_10_1007_s10620_012_2153_0
crossref_primary_10_1111_jvh_12310
crossref_primary_10_4291_wjgp_v12_i3_40
crossref_primary_10_1016_j_dld_2015_02_001
crossref_primary_10_1016_j_numecd_2021_04_016
Cites_doi 10.1002/hep.22859
10.1016/j.jhep.2006.09.020
10.1097/MEG.0b013e32830cebd7
10.1016/j.gcb.2008.09.017
10.1053/j.gastro.2004.11.018
10.1111/j.1478-3231.2008.01789.x
10.1016/j.clinbiochem.2008.06.020
10.1002/hep.22748
10.1111/j.1478-3231.2009.02101.x
10.1002/hep.22375
10.1038/ajg.2011.100
10.1016/j.jhep.2008.07.039
10.1016/j.clinbiochem.2007.08.009
10.1016/j.jhep.2006.01.007
10.1111/j.1365-2036.2008.03742.x
10.1016/j.cgh.2009.01.010
10.1016/j.jhep.2009.11.008
10.1053/jhep.2003.50346
10.1111/j.1365-2893.2006.00736.x
10.1016/j.jhep.2008.02.008
10.1002/hep.23185
10.1002/hep.23069
10.1016/j.jhep.2008.10.014
ContentType Journal Article
Contributor de Ledinghen, Victor
Lunel, Françoise
Merrouche, Wassil
Bioulac-Sage, Paulette
Bréchot, Marie-Claude
Danielou, H
Marcellin, P
Guyader, D
Garcia, Stéphane
Trocme, Candice
Rogeaux, O
Faure, Patrice
Asselah, T
Lavoinne, A
Bronowicki, J P
Beaugrand, M
Penaranda, Guillaume
Tran, Albert
Rosenthal-Allieri, A
Paradis, Valérie
Poujol, A
Bourliere, M
Lasnier, R
Maynard-Muet, M
Bourlière, Marc
Pottier, A
Michalak, Sophie
Tran, A
Ouzan, Denis
Leroy, Vincent
Metivier, S
Pol, S
Habersetzer, F
Chevailler, Alain
Couzigou, Patrice
Degott, Claude
Gelineau, M-C
Bartoli, M
Myara, A
Sturm, Nathalie
Renversez, Jean-Charles
Poupon, R
de Muret, Anne
Morel, Francoise
Vassault, A
Abergel, A
Leroy, V
Poggi, B
Bonneau, Henri Pierre
Castéra, Laurent
Trepo, C
Saint-Paul, Marie-Christine
De Ledinghen, V
Vaubourdolle, M
Le Bail, Brigitte
Goria, O
Voitot, H
Foucher, Juliette
Mathurin, Ph
Hilleret, M N
Guerber, F
Larrey, D
Mansour, Wael
Benderitter, Thierry
Ziegler, F
Ternisien, Catherine
Halfon, Philippe
Renou, Christophe
Bacq, Yannick
Boisson, R-C
Botta, Danielle
Oulès, V
Bernard, Pierre
Contributor_xml – sequence: 1
  givenname: Sophie
  surname: Michalak
  fullname: Michalak, Sophie
– sequence: 2
  givenname: Anselme
  surname: Konaté
  fullname: Konaté, Anselme
– sequence: 3
  givenname: Catherine
  surname: Ternisien
  fullname: Ternisien, Catherine
– sequence: 4
  givenname: Alain
  surname: Chevailler
  fullname: Chevailler, Alain
– sequence: 5
  givenname: Françoise
  surname: Lunel
  fullname: Lunel, Françoise
– sequence: 6
  givenname: Marie Christine
  surname: Rousselet
  fullname: Rousselet, Marie Christine
– sequence: 7
  givenname: Wael
  surname: Mansour
  fullname: Mansour, Wael
– sequence: 8
  givenname: Philippe
  surname: Halfon
  fullname: Halfon, Philippe
– sequence: 9
  givenname: Marc
  surname: Bourlière
  fullname: Bourlière, Marc
– sequence: 10
  givenname: Denis
  surname: Ouzan
  fullname: Ouzan, Denis
– sequence: 11
  givenname: Albert
  surname: Tran
  fullname: Tran, Albert
– sequence: 12
  givenname: Danielle
  surname: Botta
  fullname: Botta, Danielle
– sequence: 13
  givenname: Christophe
  surname: Renou
  fullname: Renou, Christophe
– sequence: 14
  givenname: Christophe
  surname: Sattonnet
  fullname: Sattonnet, Christophe
– sequence: 15
  givenname: Marie-Christine
  surname: Saint-Paul
  fullname: Saint-Paul, Marie-Christine
– sequence: 16
  givenname: Thierry
  surname: Benderitter
  fullname: Benderitter, Thierry
– sequence: 17
  givenname: Stéphane
  surname: Garcia
  fullname: Garcia, Stéphane
– sequence: 18
  givenname: Henri Pierre
  surname: Bonneau
  fullname: Bonneau, Henri Pierre
– sequence: 19
  givenname: Guillaume
  surname: Penaranda
  fullname: Penaranda, Guillaume
– sequence: 20
  givenname: Yannick
  surname: Bacq
  fullname: Bacq, Yannick
– sequence: 21
  givenname: Anne
  surname: de Muret
  fullname: de Muret, Anne
– sequence: 22
  givenname: Marie-Claude
  surname: Bréchot
  fullname: Bréchot, Marie-Claude
– sequence: 23
  givenname: Vincent
  surname: Leroy
  fullname: Leroy, Vincent
– sequence: 24
  givenname: Nathalie
  surname: Sturm
  fullname: Sturm, Nathalie
– sequence: 25
  givenname: Marie-Noelle
  surname: Hilleret
  fullname: Hilleret, Marie-Noelle
– sequence: 26
  givenname: Patrice
  surname: Faure
  fullname: Faure, Patrice
– sequence: 27
  givenname: Jean-Charles
  surname: Renversez
  fullname: Renversez, Jean-Charles
– sequence: 28
  givenname: Francoise
  surname: Morel
  fullname: Morel, Francoise
– sequence: 29
  givenname: Candice
  surname: Trocme
  fullname: Trocme, Candice
– sequence: 30
  givenname: Victor
  surname: de Ledinghen
  fullname: de Ledinghen, Victor
– sequence: 31
  givenname: Juliette
  surname: Foucher
  fullname: Foucher, Juliette
– sequence: 32
  givenname: Laurent
  surname: Castéra
  fullname: Castéra, Laurent
– sequence: 33
  givenname: Patrice
  surname: Couzigou
  fullname: Couzigou, Patrice
– sequence: 34
  givenname: Pierre-Henri
  surname: Bernard
  fullname: Bernard, Pierre-Henri
– sequence: 35
  givenname: Wassil
  surname: Merrouche
  fullname: Merrouche, Wassil
– sequence: 36
  givenname: Paulette
  surname: Bioulac-Sage
  fullname: Bioulac-Sage, Paulette
– sequence: 37
  givenname: Brigitte
  surname: Le Bail
  fullname: Le Bail, Brigitte
– sequence: 38
  givenname: Claude
  surname: Degott
  fullname: Degott, Claude
– sequence: 39
  givenname: Valérie
  surname: Paradis
  fullname: Paradis, Valérie
– sequence: 40
  givenname: R
  surname: Poupon
  fullname: Poupon, R
– sequence: 41
  givenname: A
  surname: Poujol
  fullname: Poujol, A
– sequence: 42
  givenname: A
  surname: Abergel
  fullname: Abergel, A
– sequence: 43
  givenname: J P
  surname: Bronowicki
  fullname: Bronowicki, J P
– sequence: 44
  givenname: J P
  surname: Vinel
  fullname: Vinel, J P
– sequence: 45
  givenname: S
  surname: Metivier
  fullname: Metivier, S
– sequence: 46
  givenname: V
  surname: De Ledinghen
  fullname: De Ledinghen, V
– sequence: 47
  givenname: J
  surname: Foucher
  fullname: Foucher, J
– sequence: 48
  givenname: O
  surname: Goria
  fullname: Goria, O
– sequence: 49
  givenname: M
  surname: Maynard-Muet
  fullname: Maynard-Muet, M
– sequence: 50
  givenname: C
  surname: Trepo
  fullname: Trepo, C
– sequence: 51
  givenname: Ph
  surname: Mathurin
  fullname: Mathurin, Ph
– sequence: 52
  givenname: D
  surname: Guyader
  fullname: Guyader, D
– sequence: 53
  givenname: H
  surname: Danielou
  fullname: Danielou, H
– sequence: 54
  givenname: O
  surname: Rogeaux
  fullname: Rogeaux, O
– sequence: 55
  givenname: S
  surname: Pol
  fullname: Pol, S
– sequence: 56
  givenname: Ph
  surname: Sogni
  fullname: Sogni, Ph
– sequence: 57
  givenname: A
  surname: Tran
  fullname: Tran, A
– sequence: 58
  givenname: P
  surname: Calès
  fullname: Calès, P
– sequence: 59
  givenname: P
  surname: Marcellin
  fullname: Marcellin, P
– sequence: 60
  givenname: T
  surname: Asselah
  fullname: Asselah, T
– sequence: 61
  givenname: M
  surname: Bourliere
  fullname: Bourliere, M
– sequence: 62
  givenname: V
  surname: Oulès
  fullname: Oulès, V
– sequence: 63
  givenname: D
  surname: Larrey
  fullname: Larrey, D
– sequence: 64
  givenname: F
  surname: Habersetzer
  fullname: Habersetzer, F
– sequence: 65
  givenname: M
  surname: Beaugrand
  fullname: Beaugrand, M
– sequence: 66
  givenname: V
  surname: Leroy
  fullname: Leroy, V
– sequence: 67
  givenname: M N
  surname: Hilleret
  fullname: Hilleret, M N
– sequence: 68
  givenname: R-C
  surname: Boisson
  fullname: Boisson, R-C
– sequence: 69
  givenname: M-C
  surname: Gelineau
  fullname: Gelineau, M-C
– sequence: 70
  givenname: B
  surname: Poggi
  fullname: Poggi, B
– sequence: 71
  givenname: J-C
  surname: Renversez
  fullname: Renversez, J-C
– sequence: 72
  givenname: Candice
  surname: Trocmé
  fullname: Trocmé, Candice
– sequence: 73
  givenname: J
  surname: Guéchot
  fullname: Guéchot, J
– sequence: 74
  givenname: R
  surname: Lasnier
  fullname: Lasnier, R
– sequence: 75
  givenname: M
  surname: Vaubourdolle
  fullname: Vaubourdolle, M
– sequence: 76
  givenname: H
  surname: Voitot
  fullname: Voitot, H
– sequence: 77
  givenname: A
  surname: Vassault
  fullname: Vassault, A
– sequence: 78
  givenname: A
  surname: Rosenthal-Allieri
  fullname: Rosenthal-Allieri, A
– sequence: 79
  givenname: A
  surname: Lavoinne
  fullname: Lavoinne, A
– sequence: 80
  givenname: F
  surname: Ziegler
  fullname: Ziegler, F
– sequence: 81
  givenname: M
  surname: Bartoli
  fullname: Bartoli, M
– sequence: 82
  givenname: C
  surname: Lebrun
  fullname: Lebrun, C
– sequence: 83
  givenname: A
  surname: Myara
  fullname: Myara, A
– sequence: 84
  givenname: F
  surname: Guerber
  fullname: Guerber, F
– sequence: 85
  givenname: A
  surname: Pottier
  fullname: Pottier, A
Copyright Copyright © 2011 American Association for the Study of Liver Diseases
2015 INIST-CNRS
Copyright © 2011 American Association for the Study of Liver Diseases.
Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml – notice: Copyright © 2011 American Association for the Study of Liver Diseases
– notice: 2015 INIST-CNRS
– notice: Copyright © 2011 American Association for the Study of Liver Diseases.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
CorporateAuthor multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies
CorporateAuthor_xml – name: multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
H94
K9.
7X8
1XC
DOI 10.1002/hep.24654
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
Hyper Article en Ligne (HAL)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE - Academic
AIDS and Cancer Research Abstracts

MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1527-3350
EndPage 67
ExternalDocumentID oai:HAL:hal-00866967v1
3958148881
21898504
25543199
10_1002_hep_24654
HEP24654
ark_67375_WNG_33H4V04Q_J
Genre article
Validation Studies
Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Program Hospitalier de Recherche Clinique (PHRC)
– fundername: French Department of Health in 1994 and 2002 for SNIFF 32
– fundername: Agence National de Recherche sur le Sida et les Hépatites (ANRS)
– fundername: FIBROSTAR HC/EP23
GroupedDBID ---
--K
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
186
1B1
1CY
1L6
1OC
1ZS
1~5
31~
33P
3O-
3SF
3WU
4.4
4G.
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AALRI
AAMMB
AANHP
AAONW
AAQFI
AAQQT
AAQXK
AASGY
AAXRX
AAXUO
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABLJU
ABMAC
ABOCM
ABPVW
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACLDA
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ACZKN
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADSXY
ADXAS
ADZMN
AECAP
AEFGJ
AEIMD
AENEX
AFBPY
AFFNX
AFGKR
AFNMH
AFUWQ
AFZJQ
AGQPQ
AGXDD
AHMBA
AHQVU
AIACR
AIDQK
AIDYY
AIQQE
AIURR
AJAOE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
F00
F01
F04
F5P
FD8
FDB
FEDTE
FGOYB
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HHY
HHZ
HVGLF
HZ~
IHE
IX1
J0M
J5H
JPC
KBYEO
KQQ
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
M65
MEWTI
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
NQ-
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
R2-
RIG
RIWAO
RJQFR
ROL
RPZ
RX1
RYL
SEW
SSZ
SUPJJ
TEORI
UB1
V2E
V9Y
W2D
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
XV2
ZGI
ZXP
ZZTAW
~IA
~WT
1OB
24P
AAHHS
ACCFJ
ADZOD
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
RGB
RWI
WIN
WRC
WUP
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
H94
K9.
7X8
1XC
ID FETCH-LOGICAL-c4874-92c78acb3511f321794ce9ca46c47da8cae8a51911207c374389571eaedd5d113
IEDL.DBID DR2
ISSN 0270-9139
1527-3350
IngestDate Thu Oct 30 06:51:09 EDT 2025
Thu Jul 10 23:51:22 EDT 2025
Wed Oct 01 14:12:30 EDT 2025
Tue Oct 07 05:54:31 EDT 2025
Mon Jul 21 06:06:04 EDT 2025
Mon Jul 21 09:16:17 EDT 2025
Wed Oct 01 04:12:58 EDT 2025
Thu Apr 24 23:10:07 EDT 2025
Wed Jan 22 16:21:19 EST 2025
Sun Sep 21 06:17:15 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Infection
Hepatic fibrosis
Viral disease
Gastroenterology
Digestive diseases
Hepatic disease
Diagnosis
Algorithm
Comparative study
Viral hepatitis C
Language English
License CC BY 4.0
Copyright © 2011 American Association for the Study of Liver Diseases.
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4874-92c78acb3511f321794ce9ca46c47da8cae8a51911207c374389571eaedd5d113
Notes Program Hospitalier de Recherche Clinique (PHRC)
Potential conflict of interest: P.C., I.F.H., and F.O. have stock ownership in BioLiveScale Inc., which has a license for FibroMeter from the University of Angers.
FIBROSTAR HC/EP23
French Department of Health in 1994 and 2002 for SNIFF 32
Agence National de Recherche sur le Sida et les Hépatites (ANRS)
Supported by the Program Hospitalier de Recherche Clinique (PHRC) of the French Department of Health in 1994 and 2002 for SNIFF 32 and the Agence National de Recherche sur le Sida et les Hépatites (ANRS) for FIBROSTAR HC/EP23.
istex:0A54D214C6902F0B45226975325AF12159FFE6B6
ArticleID:HEP24654
ark:/67375/WNG-33H4V04Q-J
fax: (33) 2 41 35 41 19
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Undefined-3
ORCID 0000-0001-6414-1951
0000-0003-4866-5274
PMID 21898504
PQID 1766825352
PQPubID 996352
PageCount 10
ParticipantIDs hal_primary_oai_HAL_hal_00866967v1
proquest_miscellaneous_912639475
proquest_miscellaneous_1776668529
proquest_journals_1766825352
pubmed_primary_21898504
pascalfrancis_primary_25543199
crossref_primary_10_1002_hep_24654
crossref_citationtrail_10_1002_hep_24654
wiley_primary_10_1002_hep_24654_HEP24654
istex_primary_ark_67375_WNG_33H4V04Q_J
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-01
January 2012
2012-01-00
2012
2012-Jan
20120101
PublicationDateYYYYMMDD 2012-01-01
PublicationDate_xml – month: 01
  year: 2012
  text: 2012-01
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken, NJ
– name: United States
PublicationTitle Hepatology (Baltimore, Md.)
PublicationTitleAlternate Hepatology
PublicationYear 2012
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley
Wolters Kluwer Health, Inc
Wiley-Blackwell
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley
– name: Wolters Kluwer Health, Inc
– name: Wiley-Blackwell
References Cales P, De Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, et al. Evaluating accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-1362.
Zarski H, Sturm N, Guechot J, Paris A. Independent and prospective comparison of 9 surrogate markers for the diagnosis of liver fibrosis in chronic hepatitis C [Abstract]. Hepatology 2009; 50( Suppl 4): 1061A.
Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 395-402.
Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41.
Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-693.
Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198.
Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-670.
Boursier J, Cales P. Combination of fibrosis tests: sequential or synchronous? Hepatology 2009; 50: 656-657.
Cales P, Veillon P, Konate A, Mathieu E, Ternisien C, Chevailler A, et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008; 41: 10-18.
Boursier J, De Ledinghen V, Zarski J, Rousselet MC, Sturm N, Foucher J, et al. A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011; 106: 1255-1263.
Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431.
Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28: 458-467.
Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41: 1368-1376.
Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
Cales P, Boursier J, de Ledinghen V, Halfon P, Bacq Y, Leroy V, et al. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol 2008; 32: 1050-1060.
Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-1089.
Boursier J, Bacq Y, Halfon P, Leroy V, De Ledinghen V, De Muret A, et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21: 28-38.
Becker L, Salameh W, Sferruzza A, Zhang K, Chen R, Malik R, et al. Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2009; 7: 696-701.
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
Rashid M, Mitchell JD, Cramp ME, Cross TJ. Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C. Hepatology 2010; 51: 354-355.
Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507-1515.
Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.
Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-1827.
2009; 21
2011; 106
2006; 13
2009; 50
2006; 44
2005; 128
2008; 28
2008; 48
2003; 38
2009; 7
2008; 32
2008; 41
2009; 49
2010; 52
2007; 46
2010; 51
2009; 29
Zarski (R15-9-20241201) 2009; 50
Cales (R13-9-20241201) 2008; 28
Sebastiani (R2-9-20241201) 2006; 44
Castera (R1-9-20241201) 2005; 128
Mehta (R24-9-20241201) 2009; 50
Bedossa (R23-9-20241201) 2009; 50
Sebastiani (R6-9-20241201) 2009; 49
Cales (R12-9-20241201) 2008; 32
Bourliere (R3-9-20241201) 2006; 13
Boursier (R10-9-20241201) 2009; 21
Boursier (R11-9-20241201) 2009; 50
Wai (R17-9-20241201) 2003; 38
Thein (R22-9-20241201) 2008; 48
Becker (R5-9-20241201) 2009; 7
Rashid (R9-9-20241201) 2010; 51
Castera (R7-9-20241201) 2010; 52
Boursier (R8-9-20241201) 2009; 29
Cales (R18-9-20241201) 2008; 41
Leroy (R16-9-20241201) 2008; 41
Bourliere (R4-9-20241201) 2008; 28
Boursier (R14-9-20241201) 2011; 106
Castera (R19-9-20241201) 2008; 48
Lucidarme (R20-9-20241201) 2009; 49
Halfon (R21-9-20241201) 2007; 46
22162013 - Hepatology. 2012 Feb;55(2):652-3; author reply 653
References_xml – reference: Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
– reference: Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
– reference: Boursier J, Cales P. Combination of fibrosis tests: sequential or synchronous? Hepatology 2009; 50: 656-657.
– reference: Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507-1515.
– reference: Boursier J, Bacq Y, Halfon P, Leroy V, De Ledinghen V, De Muret A, et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21: 28-38.
– reference: Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 395-402.
– reference: Boursier J, De Ledinghen V, Zarski J, Rousselet MC, Sturm N, Foucher J, et al. A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011; 106: 1255-1263.
– reference: Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41.
– reference: Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431.
– reference: Cales P, De Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, et al. Evaluating accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-1362.
– reference: Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198.
– reference: Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-1089.
– reference: Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-1827.
– reference: Rashid M, Mitchell JD, Cramp ME, Cross TJ. Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C. Hepatology 2010; 51: 354-355.
– reference: Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41: 1368-1376.
– reference: Becker L, Salameh W, Sferruzza A, Zhang K, Chen R, Malik R, et al. Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2009; 7: 696-701.
– reference: Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
– reference: Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.
– reference: Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-670.
– reference: Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28: 458-467.
– reference: Cales P, Boursier J, de Ledinghen V, Halfon P, Bacq Y, Leroy V, et al. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol 2008; 32: 1050-1060.
– reference: Zarski H, Sturm N, Guechot J, Paris A. Independent and prospective comparison of 9 surrogate markers for the diagnosis of liver fibrosis in chronic hepatitis C [Abstract]. Hepatology 2009; 50( Suppl 4): 1061A.
– reference: Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-693.
– reference: Cales P, Veillon P, Konate A, Mathieu E, Ternisien C, Chevailler A, et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008; 41: 10-18.
– volume: 52
  start-page: 191
  year: 2010
  end-page: 198
  article-title: Prospective comparison of two algorithms combining non‐invasive methods for staging liver fibrosis in chronic hepatitis C
  publication-title: J Hepatol
– volume: 21
  start-page: 28
  year: 2009
  end-page: 38
  article-title: Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C
  publication-title: Eur J Gastroenterol Hepatol
– volume: 128
  start-page: 343
  year: 2005
  end-page: 350
  article-title: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
  publication-title: Gastroenterology
– volume: 51
  start-page: 354
  year: 2010
  end-page: 355
  article-title: Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C
  publication-title: Hepatology
– volume: 7
  start-page: 696
  year: 2009
  end-page: 701
  article-title: Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection
  publication-title: Clin Gastroenterol Hepatol
– volume: 50
  start-page: 1061A
  issue: Suppl 4
  year: 2009
  article-title: Independent and prospective comparison of 9 surrogate markers for the diagnosis of liver fibrosis in chronic hepatitis C [Abstract]
  publication-title: Hepatology
– volume: 46
  start-page: 395
  year: 2007
  end-page: 402
  article-title: Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C
  publication-title: J Hepatol
– volume: 50
  start-page: 656
  year: 2009
  end-page: 657
  article-title: Combination of fibrosis tests: sequential or synchronous?
  publication-title: Hepatology
– volume: 41
  start-page: 10
  year: 2008
  end-page: 18
  article-title: Reproducibility of blood tests of liver fibrosis in clinical practice
  publication-title: Clin Biochem
– volume: 28
  start-page: 1352
  year: 2008
  end-page: 1362
  article-title: Evaluating accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C
  publication-title: Liver Int
– volume: 13
  start-page: 659
  year: 2006
  end-page: 670
  article-title: Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies
  publication-title: J Viral Hepat
– volume: 106
  start-page: 1255
  year: 2011
  end-page: 1263
  article-title: A new combination of blood test and Fibroscan for accurate non‐invasive diagnosis of liver fibrosis stages in chronic hepatitis C
  publication-title: Am J Gastroenterol
– volume: 29
  start-page: 1507
  year: 2009
  end-page: 1515
  article-title: The combination of a blood test and Fibroscan improves the non‐invasive diagnosis of liver fibrosis
  publication-title: Liver Int
– volume: 41
  start-page: 1368
  year: 2008
  end-page: 1376
  article-title: Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta‐analysis with individual data
  publication-title: Clin Biochem
– volume: 50
  start-page: 1
  year: 2009
  end-page: 3
  article-title: Liver biopsy: the best, not the gold standard
  publication-title: J Hepatol
– volume: 50
  start-page: 36
  year: 2009
  end-page: 41
  article-title: Exceeding the limits of liver histology markers
  publication-title: J Hepatol
– volume: 44
  start-page: 686
  year: 2006
  end-page: 693
  article-title: Stepwise combination algorithms of non‐invasive markers to diagnose significant fibrosis in chronic hepatitis C
  publication-title: J Hepatol
– volume: 49
  start-page: 1821
  year: 2009
  end-page: 1827
  article-title: SAFE biopsy: a validated method for large‐scale staging of liver fibrosis in chronic hepatitis C
  publication-title: Hepatology
– volume: 48
  start-page: 418
  year: 2008
  end-page: 431
  article-title: Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression
  publication-title: Hepatology
– volume: 32
  start-page: 1050
  year: 2008
  end-page: 1060
  article-title: Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests
  publication-title: Gastroenterol Clin Biol
– volume: 49
  start-page: 1083
  year: 2009
  end-page: 1089
  article-title: Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C
  publication-title: Hepatology
– volume: 28
  start-page: 458
  year: 2008
  end-page: 467
  article-title: Optimized stepwise combination algorithms of non‐invasive liver fibrosis scores including Hepascore in hepatitis C virus patients
  publication-title: Aliment Pharmacol Ther
– volume: 38
  start-page: 518
  year: 2003
  end-page: 526
  article-title: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
  publication-title: Hepatology
– volume: 48
  start-page: 835
  year: 2008
  end-page: 847
  article-title: Non‐invasive evaluation of liver fibrosis using transient elastography
  publication-title: J Hepatol
– volume: 49
  start-page: 1821
  year: 2009
  ident: R6-9-20241201
  article-title: SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
  publication-title: Hepatology
  doi: 10.1002/hep.22859
– volume: 46
  start-page: 395
  year: 2007
  ident: R21-9-20241201
  article-title: Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.09.020
– volume: 21
  start-page: 28
  year: 2009
  ident: R10-9-20241201
  article-title: Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0b013e32830cebd7
– volume: 32
  start-page: 1050
  year: 2008
  ident: R12-9-20241201
  article-title: Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.
  publication-title: Gastroenterol Clin Biol
  doi: 10.1016/j.gcb.2008.09.017
– volume: 50
  start-page: 1061A
  issue: Suppl 4
  year: 2009
  ident: R15-9-20241201
  article-title: Independent and prospective comparison of 9 surrogate markers for the diagnosis of liver fibrosis in chronic hepatitis C Abstract.
  publication-title: Hepatology
– volume: 128
  start-page: 343
  year: 2005
  ident: R1-9-20241201
  article-title: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.11.018
– volume: 28
  start-page: 1352
  year: 2008
  ident: R13-9-20241201
  article-title: Evaluating accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.
  publication-title: Liver Int
  doi: 10.1111/j.1478-3231.2008.01789.x
– volume: 41
  start-page: 1368
  year: 2008
  ident: R16-9-20241201
  article-title: Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data.
  publication-title: Clin Biochem
  doi: 10.1016/j.clinbiochem.2008.06.020
– volume: 49
  start-page: 1083
  year: 2009
  ident: R20-9-20241201
  article-title: Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C.
  publication-title: Hepatology
  doi: 10.1002/hep.22748
– volume: 29
  start-page: 1507
  year: 2009
  ident: R8-9-20241201
  article-title: The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
  publication-title: Liver Int
  doi: 10.1111/j.1478-3231.2009.02101.x
– volume: 48
  start-page: 418
  year: 2008
  ident: R22-9-20241201
  article-title: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.
  publication-title: Hepatology
  doi: 10.1002/hep.22375
– volume: 106
  start-page: 1255
  year: 2011
  ident: R14-9-20241201
  article-title: A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.100
– volume: 50
  start-page: 36
  year: 2009
  ident: R24-9-20241201
  article-title: Exceeding the limits of liver histology markers.
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2008.07.039
– volume: 41
  start-page: 10
  year: 2008
  ident: R18-9-20241201
  article-title: Reproducibility of blood tests of liver fibrosis in clinical practice.
  publication-title: Clin Biochem
  doi: 10.1016/j.clinbiochem.2007.08.009
– volume: 44
  start-page: 686
  year: 2006
  ident: R2-9-20241201
  article-title: Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.01.007
– volume: 28
  start-page: 458
  year: 2008
  ident: R4-9-20241201
  article-title: Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2008.03742.x
– volume: 7
  start-page: 696
  year: 2009
  ident: R5-9-20241201
  article-title: Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection.
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2009.01.010
– volume: 52
  start-page: 191
  year: 2010
  ident: R7-9-20241201
  article-title: Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2009.11.008
– volume: 38
  start-page: 518
  year: 2003
  ident: R17-9-20241201
  article-title: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.
  publication-title: Hepatology
  doi: 10.1053/jhep.2003.50346
– volume: 13
  start-page: 659
  year: 2006
  ident: R3-9-20241201
  article-title: Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
  publication-title: J Viral Hepat
  doi: 10.1111/j.1365-2893.2006.00736.x
– volume: 48
  start-page: 835
  year: 2008
  ident: R19-9-20241201
  article-title: Non-invasive evaluation of liver fibrosis using transient elastography.
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2008.02.008
– volume: 51
  start-page: 354
  year: 2010
  ident: R9-9-20241201
  article-title: Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C.
  publication-title: Hepatology
  doi: 10.1002/hep.23185
– volume: 50
  start-page: 656
  year: 2009
  ident: R11-9-20241201
  article-title: Combination of fibrosis tests: sequential or synchronous?
  publication-title: Hepatology
  doi: 10.1002/hep.23069
– volume: 50
  start-page: 1
  year: 2009
  ident: R23-9-20241201
  article-title: Liver biopsy: the best, not the gold standard.
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2008.10.014
– reference: 22162013 - Hepatology. 2012 Feb;55(2):652-3; author reply 653
SSID ssj0009428
Score 2.3995638
Snippet The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate...
The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate...
UNLABELLED: The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate...
SourceID hal
proquest
pubmed
pascalfrancis
crossref
wiley
istex
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 58
SubjectTerms Accuracy
Adult
Algorithms
Biological and medical sciences
Biological Markers
Biomarkers - blood
Biopsy
Classification
Decision Trees
Diagnostic Techniques, Digestive System
Diagnostic Techniques, Digestive System - standards
Elasticity Imaging Techniques
Female
Gastroenterology
Gastroenterology - methods
Gastroenterology - standards
Gastroenterology. Liver. Pancreas. Abdomen
Hepatitis
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic
Hepatitis C, Chronic - classification
Hepatitis C, Chronic - diagnosis
Hepatology
Human health and pathology
Human viral diseases
Humans
Hépatology and Gastroenterology
Infectious diseases
Life Sciences
Liver
Liver Cirrhosis
Liver Cirrhosis - classification
Liver Cirrhosis - diagnosis
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Other diseases. Semiology
Reproducibility of Results
Sensitivity and Specificity
Viral diseases
Viral hepatitis
Title Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive
URI https://api.istex.fr/ark:/67375/WNG-33H4V04Q-J/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.24654
https://www.ncbi.nlm.nih.gov/pubmed/21898504
https://www.proquest.com/docview/1766825352
https://www.proquest.com/docview/1776668529
https://www.proquest.com/docview/912639475
https://hal.science/hal-00866967
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1527-3350
  dateEnd: 20241102
  omitProxy: true
  ssIdentifier: ssj0009428
  issn: 0270-9139
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0270-9139
  databaseCode: DR2
  dateStart: 19960101
  customDbUrl:
  isFulltext: true
  eissn: 1527-3350
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009428
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGkBAvfDMCYzIIob2kSxw7juFpqjaqiU2AGOwByXIch1YrbdW0E_DO_82d81GKNgnxlo9zHDvn8-_sy-8IeZHbDAyjK8M8lWXIrRKhKYwMbeE4szBDCp-m8_gkHZzyozNxtkFet__C1PwQ3YIbjgxvr3GAm7zaW5GGDt2sx5ANDOxvnKTenfqwoo5S3OdVBa8rwt1l1bIKRWyvK7k2F10bYiTkdezc7xghaSropLLObnEZ_FxHs346OrxNvrQNqaNQznvLRd6zP__iePzPlt4htxqYSvdrvbpLNtzkHrlx3GzE3ye_-l3-QjotqV9fpUUdtgdFqBl_nc5Hi-G3igIqpmOM_qAlvMW0GlV0NKFQGyoqnPRfUYD2f5Ywc0cx_pfOkHqjctRMCopRTXM3_kEnuIB8YTDs_gE5PTz42B-ETUaH0IJjxEPFrMyMzXH3skwYGgPrlDU8tVwWJrPGZQYwJYDASNpEYmp2IWNnXFGIIo6Th2QTanGPCE1Bk6RVGXMi505EJjaANQoFeMRkUrGA7LbfVtuG7hyzbox1TdTMNDRU-24NyPNOdFZzfFwqBArS3UdW7sH-W43X0C1MVSov4oC89PrTiZn5OUbOSaE_n7zRSTLgnyL-Xh8FZGdNwboC4OEBpFMqINutxunGqlQayTzBowfMHJBn3W2wB7jJYyZuukQZEEozweAR9AoZFTMAplyKgGzVyryqP85UJiJo7q5Xyas7RA8O3vmDx_8u-oTcBMDJ6iWsbbK5mC_dUwB1i3zHj97f25FG2w
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELf2IcFe-P4IjGEQQntJl7h2HCNepmojjLYCtI29IMtxnLVaaaumnYB3_m_ukjalaJMQb01zrmP3fP7d-fI7Ql6lNgbD6HI_jWTuc6uEbzIjfZs5zizskKIs09npRskJPzoTZ2vk7eJdmIofog644coo7TUucAxI7y1ZQ3tu3GBIB7ZONnkEfgpCos9L8ijFy8qq4HcFeL6sFrxCAdurm67sRus9zIXcxOn9jjmSpoBpyqv6FlcB0FU8W25Ih7fJ18VQqjyUi8Zsmjbsz79YHv93rHfIrTlSpfuVat0la254j9zozM_i75NfrbqEIR3ltAyx0qzK3IMm1AzOR5P-tPetoACM6QATQGgOjzEq-gXtDyn0hroKF603FND9ny3MxFFMAaZjZN8oHDXDjGJi08QNftAhxpAvDWbePyAnhwfHrcSfF3XwLfhG3FfMytjYFA8w8yZDe2CdsoZHlsvMxNa42ACsBBwYSNuUWJ1dyNAZl2UiC8PmQ7IBvbjHhEagTNKqmDmRcicCExqAG5kCSGJiqZhHdhd_rrZzxnMsvDHQFVcz0zBQXU6rR17WouOK5uNKIdCQ-j4Scyf7bY3foWcYqUhehh55XSpQLWYmF5g8J4X-0n2nm82Enwb8kz7yyM6KhtUNwMkDVKeUR7YXKqfnhqXQyOcJTj3AZo-8qG-DScBzHjN0oxnKgFAUCwY_Qa-RUSEDbMql8MijSpuX_YexikUAw90tdfL6CdHJwcfyw5N_F31ObibHnbZuv-9-eEq2AH-yKqK1TTamk5l7Bhhvmu6US_k3NjRK_A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD7aRZp44X4JjGEQQntJl7hOHCNepm6ljG0aiI29IMtxHFqttFXTTsA7_5tzkjalaJMQb01zXMfusf0d-8t3AF6mNsGJ0eV-GsvcF1ZFvsmM9G3mBLe4QkZlms6j47hzKg7Oo_MVeDN_F6bSh6g33GhklPM1DXA3yvKdhWpo140anOTAVmFdRCohQt_ex4V4lBJlZlWMuwI6X1ZzXaGA79RFl1aj1S5xIdepe78TR9IU2E15ld_iKgC6jGfLBal9C77Mm1LxUC4a00nasD__Unn837behpszpMp2K9e6AytucBc2jmZn8ffgV6tOYciGOSu3WFlWMfewCDP9r8Nxb9L9VjAExqxPBBCW42MMi17BegOGtZGv4kXrNUN0_2cJM3aMKMBsROobhWNmkDEiNo1d_wcb0B7ypSHm_X04be9_anX8WVIH32JsJHzFrUyMTekAM29ymg-sU9aI2AqZmcQalxiElYgDA2mbkrKzRzJ0xmVZlIVh8wGsYS3uEbAYnUlalXAXpcJFgQkNwo1MISQxiVTcg-35n6vtTPGcEm_0daXVzDU2VJfd6sGL2nRUyXxcaYQeUt8nYe7O7qGm7ygyjFUsL0MPXpUOVJuZ8QWR52SkPx-_1c1mR5wF4oM-8GBrycPqAhjkIapTyoPNucvp2cRSaNLzxKAeYbMHz-vbOCXQOY8ZuOGUbNAoTiKOP8GusVEhR2wqZOTBw8qbF_WHCQ6mAJu7Xfrk9R2iO_sn5YfH_276DDZO9tr68N3x-ydwA-Enrza0NmFtMp66pwjxJulWOZJ_A3lmSoA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Eight+Diagnostic+Algorithms+for+Liver+Fibrosis+in+Hepatitis+C%3A+New+Algorithms+Are+More+Precise+and+Entirely+Noninvasive&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=BOURSIER%2C+J%C3%A9r%C3%B4me&rft.au=DE+LEDINGHEN%2C+Victor&rft.au=ZARSKI%2C+Jean-Pierre&rft.au=FOUCHARD-HUBERT%2C+Isabelle&rft.date=2012&rft.pub=Wiley&rft.issn=0270-9139&rft.volume=55&rft.issue=1&rft.spage=58&rft.epage=67&rft_id=info:doi/10.1002%2Fhep.24654&rft.externalDBID=n%2Fa&rft.externalDocID=25543199
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon